Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04203485 Not yet recruiting - Clinical trials for PD-L1 Positive Non-small Cell Lung Cancer

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Start date: June 15, 2020
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.

NCT ID: NCT04201886 Not yet recruiting - Clinical trials for Rheumatoid Arthritis and Osteoarthritis

Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis

Start date: January 2020
Phase: Phase 4
Study type: Interventional

Assessment of the serum level of calprotectin in patients with rheumatoid arthritis and osteoarthritis.

NCT ID: NCT04195997 Not yet recruiting - Clinical trials for Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk

Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

The study is an investigator-sponsored, prospective, multicenter, randomized, open-label study designed to compare efficacy and safety between bivalirudin and heparin in patients with non-valvular atrial fibrillation undergoing percutaneous left atrial appendage occlusion.

NCT ID: NCT04195126 Not yet recruiting - Burns Clinical Trials

Early Haemadsorption in Major Burns

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Major deep burns (>20% body surface, involving deep skin layers) and associated severe inflammatory reaction and their complication are one of the biggest challenge of intensive care. Haemoadsorption therapy, including the CytoSorb treatment is a promising novel therapeutic approach, but only case-studies are available in the literature yet. Based on data from septic shock patient treatment the investigators hypothesize that CytoSorb is beneficial in early treatment of burns. The investigators aim to conduct a randomised-controlled study to assess the clinical effectiveness (based on score systems including MODS, SOFA, APACHE II, KDIGO, ABSI), 7 and 28 days survival, intensive care length of stay, length of mechanical ventilation, resuscitation fluid need and ino/vasopressor drug doses and the presence and severity of organ dysfunctions, particularly renal dysfunction. The investigatora plan to conduct basic research to elucidate the pathophysiological background of clinical effect, including the measurement of inflammatory and anti-inflammatory cytokines, presence and severity of oxidative stress (lipid peroxidation, protein oxidation, reduced/oxidised glutathion levels) and organ dysfunction markers (kidney injury molecule -1, neutrophil gelatinase-associated lipocalin, cystatin-C, uromodulin).

NCT ID: NCT04193839 Not yet recruiting - Adverse Drug Event Clinical Trials

Reducing Errors In The Neonatal Intensive Care Unit

SAPHET-i
Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

This is a monocentric prospective pre and post-intervention study, aiming at analyzing the efficacy of the Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA) as compared to paper order entry in reducing medication erros (MEs) in the Neonatal Intensive Care Unit (NICU)

NCT ID: NCT04192812 Not yet recruiting - Uterine Fibroid Clinical Trials

PREOPERATIVE GONADOTROPINE-RELEASING HORMONE AGONIST THERAPY BEFORE SURGERY FOR UTERİN FIBROIDS

Start date: December 30, 2020
Phase: N/A
Study type: Interventional

Uterin fibroids are the most common operation indication for hysterectomy. Dyring laparoscopic hysterectomy the amount of bleeding is a great difficulty.There are a lot of clinical researchs to reduce the haemorrhage during open hysterectomy but not laparoscopic procedure. In ALKU ERH clinic, researchers decided to smaller the size of fibroid by using GnRH analogues before total laparoscopic hysterectomy to reduce the haemorrhage amount.

NCT ID: NCT04191590 Not yet recruiting - Clinical trials for Chronic Rhinosinusitis (Diagnosis)

Impact of Chronic Rhinosinusitis on the Index of Ciliary Beat Efficiency Using Fluorescent Nanosticks: (R-IMPAC)

R-IMPAC
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Impact of chronic rhinosinusitis on the index of ciliary beat efficiency using fluorescent nanosticks

NCT ID: NCT04190472 Not yet recruiting - Recurrence Clinical Trials

Intraoperative HPV Testing Evaluation

Start date: June 1, 2020
Phase:
Study type: Observational

High-grade intraepithelial lesion/cervical intraepithelial neoplasia grade 2-3 is a premalignant cervical lesion caused by persistent high-risk human papillomavirus infection. Human papillomavirus test is a very sensitive risk marker of cervical cancer and it has been incorporated in the follow-up after high-grade intraepithelial lesion treatment. Papillomavirus test performed intraoperatively could be a beneficial approach to anticipate treatment failure, allow for early management and consequently a reduction in costs. The aim of this study is to evaluate if the IOP-HPV test has non-inferior diagnostic utility of HSIL/CIN2-3 recurrence at 24 months as the HPV test performed 6 months after treatment.

NCT ID: NCT04190316 Not yet recruiting - Clinical trials for ESBL-producing Enterobacteriaceae Infections

Factors Influencing the Fecal Relative Abundance of ESBL-producing Enterobacteriaceae in Intensive Care (BLSE-REA).

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Extended-Spectrum Beta-Lactamases (ESBL)-Producing Enterobacteriaceae (PE) pose a major problem among antimicrobial resistance. The worldwide spread of theses bacteria may be responsible for 10 million death in 2050. Infection with ESBL-PE are associated with a worse prognosis because of delay in the start of adequate antibiotic treatment, especially for severe infections. It has been proposed to identify colonized patients to predict the risk of infection and the risk of nosocomial cross transmission. This qualitative approach has limit as only 5 to 20% of patients will develop an infection with ESBL-PE. The fecal relative abundance (RA) of ESBL-PE is a ratio of ESBL-PE among enterobacteriaceae that could identify high-risk patients of infection or cross transmission. ESBL-PE RA may be highly variable in patient with antibiotic exposure depending on the molecule received but dynamic data is missing. The aim of this study is to identify the factor that influence the fecal RA of ESBL-PE in ICU and to evaluate the association between different level of fecal RA and infection or cross transmission with an ESBL-PE.

NCT ID: NCT04189094 Not yet recruiting - Clinical trials for Small Cell Lung Cancer Limited Stage

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

The study is a prospective, multi-center, open-label, randomized, and controlled phase II clinical trial.